Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of alemtuzumab in unrelated donor reduced-intensity allogeneic hematopoietic transplantation for hematologic malignancies
2007-006440-22Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in hematopoietic malignancies, sponsored by GELTAMO. Primary endpoints: Incidence of acute graft-versus-host disease, Severity of acute graft-versus-host disease and 3 more. Started Mar 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2007-006440-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006440-22.